IRLAB announces that equity research company Edison initiates coverage of the company

June 2, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that equity research company Edison Investment Research has been engaged by IRLAB to produce regular, in-depth research on the company. The intention is to raise the visibility of the company and enable investors and stakeholders to develop an improved understanding of the business.

[mfn_before_post]

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that equity research company Edison Investment Research has been engaged by IRLAB to produce regular, in-depth research on the company. The intention is to raise the visibility of the company and enable investors and stakeholders to develop an improved understanding of the business.

Edison's research is read on a free-to-access basis by individuals and institutions across the globe. Edison's coverage of IRLAB is available on IRLAB’s website, www.irlab.se, as well as on Edison’s website, www.edisongroup.com/company/irlab-therapeutics.

“It is important that investors are given the opportunity to acquire different perspectives on IRLAB’s operations and the value potential of IRLAB’s share. Engaging Edison is part of our commitment to increase analyst coverage of the company and will be followed by additional research from other banks and analysts ahead,” said Viktor Siewertz, CFO at IRLAB.

For more information

Nicholas Waters, CEO
Phone: +46 730 75 77 01
E-mail: nicholas.waters@irlab.se

Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (the Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.

Attachments

IRLAB announces that equity research company Edison initiates coverage of the company

[mfn_after_post]

Documents & Links